We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Ebolavirus Triage Test Developed

By LabMedica International staff writers
Posted on 26 Feb 2015
A Rapid Ebolavirus Triage Test is designed to enable healthcare workers, even in challenging environments, to test blood samples and aims at providing accurate and fast diagnosis of Ebola. The test is designed to offer a unique combination of speed, sensitivity, accuracy and ease-of-use required for outbreaks where time is of the essence.

The test uses 0.2 mL blood that is added directly to the Idylla cartridge, which contains all necessary reagents on board for performing the analysis on Biocartis (Mechelen, Belgium) fully automated, molecular diagnostics system. A complete analysis of the sample takes around 90 minutes and can be operated by healthcare professional in most settings, including in the field, making the test ideal for use in regions with limited infrastructure.

Image: The Idylla cartridge fully automated, molecular diagnostics system (Photo courtesy of Biocartis).
Image: The Idylla cartridge fully automated, molecular diagnostics system (Photo courtesy of Biocartis).

The Rapid Ebola Virus Triage Test was developed in association with Janssen Diagnostics (Beerse, Belgium) and the Institute for Tropical Medicine (Antwerp, Belgium) for its Idylla system, a fully automated molecular diagnostic platform that is CE-IVD marked in Europe. The company believes its Rapid Ebola Virus Triage Test could provide a sustainable solution for rapid detection of Ebola-infected patients even after the current Ebola outbreak. After testing of synthetic virus samples in Belgium and the USA, Biocartis has now registered for field-testing in West Africa to gather additional clinical evidence for the test performance.

Rudi Pauwels, PhD, Biocartis' Chief Executive Officer commented, “This test aims not only to improve the diagnosis of the Ebola virus for hard-pressed healthcare professionals in the field, but to lay the foundations for a better and faster diagnostic infrastructure after the current outbreak has receded, both in this region and around the world. One of the lessons of the Ebola outbreak has been the urgent need for faster and more accurate diagnostics. Biocartis is pleased to be working, alongside prestigious partners, on what it believes could offer a viable solution for healthcare workers around the world to enable faster testing of infectious diseases in virtually any setting.”

Related Links:

Biocartis
Janssen Diagnostics 
Belgian Institute for Tropical Medicine 



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Latest Microbiology News

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle

New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier